>Mercado de medicamentos para la hiperoxaluria secundaria en Oriente Medio y África, por tipo (relaxaliasa, diuréticos tiazídicos y suplementos), tipo de medicamento (con receta y sin receta), tipo de población (niños y adultos), usuario final (hospitales, clínicas especializadas, atención médica domiciliaria y otros), canal de distribución (farmacias hospitalarias, farmacias minoristas, farmacias en línea y otras), país (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Egipto y el resto de Oriente Medio y África), tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de medicamentos contra la hiperoxaluria secundaria en Oriente Medio y África
Se espera que el mercado de medicamentos para la hiperoxaluria secundaria gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 67,3% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 8.346,46 millones para 2028. La pérdida de oxalobacter formigenes debido a la alta ingesta de antibióticos y la baja conciencia dietética probablemente sean impulsores clave del mercado de medicamentos para la hiperoxaluria secundaria.
La creciente conciencia sobre la carga de la enfermedad y el aumento de la inversión en I+D de medicamentos específicos para la hiperoxaluria secundaria son los impulsores clave del crecimiento del mercado de medicamentos para la hiperoxaluria secundaria.
Una enfermedad multifactorial que afecta a diferentes órganos y tejidos causada por la absorción de altas concentraciones de oxalato debido a problemas intestinales se conoce como hiperoxaluria secundaria o, en su etapa más extrema, conocida como hiperoxaluria entérica. Esta enfermedad está muy relacionada con la dieta y la malabsorción causada por alguna enfermedad, ya que la ingestión de oxalato o precursores de oxalato, como la vitamina C, es una de las principales causas de la enfermedad. Oxalobacter formigenes, una bacteria que se sabe que es el factor crítico de la hiperoxaluria secundaria, utiliza el oxalato como el elemento energético clave para completar su requerimiento funcional, y desempeña un papel importante en la aparición de la enfermedad.
Como medida preventiva, se deben tomar alimentos bajos en oxalato, pero en países que tienen un estilo de vida socioeconómico altamente desarrollado, como los EE. UU., Europa y China, los hábitos dietéticos no son adecuados y la falta de conciencia dietética es la principal causa de hiperoxaluria secundaria, que se espera que impulse el mercado de medicamentos para la hiperoxaluria secundaria. Los ingresos operativos son limitados en caso de hiperoxaluria secundaria debido al hecho de que un menor número de pacientes objetivo conduce a menores ingresos de ese segmento operativo y se espera que actúe como restricción para el crecimiento del mercado de medicamentos para la hiperoxaluria secundaria. La dieta baja en oxalato es difícil de mantener ya que las personas la consumen directamente o toman el precursor de oxalato. El mercado brinda oportunidades en ambos aspectos, ya sea para hacer una dieta baja en oxalato o, por otro lado, se espera que la dificultad para mantener una dieta baja en oxalato actúe como una oportunidad para el crecimiento del mercado de medicamentos para la hiperoxaluria secundaria. La terapia de reemplazo renal es el siguiente paso después de que el paciente ignora la medicación y otros productos nutricionales, lo que afectará significativamente el uso del producto para el tratamiento medicinal y conducirá a una mayor demanda de terapia de reemplazo renal, que se espera que actúe como un desafío para el crecimiento del mercado de medicamentos para la hiperoxaluria secundaria.
El informe de mercado de medicamentos para la hiperoxaluria secundaria proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de medicamentos para la hiperoxaluria secundaria, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de medicamentos contra la hiperoxaluria secundaria
El mercado secundario de medicamentos para la hiperoxaluria se clasifica en cinco segmentos notables que se basan en el tipo, el tipo de medicamento, el tipo de población, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- On the basis of type, the secondary hyperoxaluria drug market is segmented into reloxaliase, thiazide diuretics and supplements. In 2021, supplements segment is dominating in the secondary hyperoxaluria drug market as there is no targeted therapy available. However, some products are in the clinical trials and are expected to come to interstate commerce in near future. So management of the disease is done through supplements and dietary restrictions. Calcium supplements, magnesium supplements and other supplements serve as primary line of treatment along with dietary restrictions, fluid intake and probiotics which are used to maintain the gut flora.
- On the basis of drug type, the secondary hyperoxaluria drug market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating in the secondary hyperoxaluria drug market as among all the products available for the treatment are generally supplements. After the successful diagnosis of the disease, the treatments suggested by physicians are available over the counter and a prescription is not necessary for these supplements to be consumed with regular diet owing to the reason for over the counter to dominate in the secondary hyperoxaluria drug market.
- On the basis of population type, the secondary hyperoxaluria drug market is segmented into children and adults. In 2021, adults segment is dominating in the secondary hyperoxaluria drug market as the diagnosis for secondary hyperoxaluria adults is usually carried out for indications of kidney stone and high oxalate excretion in the urine along with UTI. The prevalence of kidney stones is uncommon in children and the number of cases for the disease is comparatively very low when compared with adults.
- On the basis of end user, the secondary hyperoxaluria drug market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the secondary hyperoxaluria drug market owing to the fact that the current treatment comprises of supplements and thiazide diuretics. These treatment products are taken by patients at home without the help of any medical professional and supervision hence dominating the segment of the secondary hyperoxaluria drug market.
- On the basis of distribution channel, the secondary hyperoxaluria drug market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the secondary hyperoxaluria drug market as the numbers of these pharmacies are very high and increasing with year passing. They cater to majority of patients for buying drugs in traditional consumer purchase style. Moreover, retail pharmacies are focusing on broadening their services for better customer service.
Secondary Hyperoxaluria Drug Market Country Level Analysis
The secondary hyperoxaluria drug market is analysed and market size information is provided by the country, type, drug type, population type, end user and distribution channel as referenced above.
The countries covered in the secondary hyperoxaluria drug market report are South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing usage of dandruff treatment product and rising awareness about it. South Africa is expected to dominate in the market in the Middle East and Africa market due to rapidly increasing product usage and diagnosis rate with rising awareness regarding secondary hyperoxaluria.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Difficulty in Maintaining Low Oxalate Diet and Regulatory Support for Approval are Creating New Opportunities in the Secondary Hyperoxaluria Drug Market
Secondary hyperoxaluria drug market also provides you with detailed market analysis for every country growth in particular industry with secondary hyperoxaluria drug product sales, impact of advancement in the secondary hyperoxaluria drug and changes in regulatory scenarios with their support for the secondary hyperoxaluria drug market. The data is available for historic period 2019 to 2020.
Competitive Landscape and Secondary Hyperoxaluria Drug Market Share Analysis
Secondary hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to secondary hyperoxaluria drug market.
The major companies providing secondary hyperoxaluria drug market are Celebrate Vitamins, Synlogic, GlaxoSmithKline plc, Bayer AG, Nestlé, TIENS, and Now Foods, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately
Numerosas empresas de todo el mundo también han iniciado lanzamientos de productos y han firmado acuerdos que también están acelerando el mercado secundario de fármacos para la hiperoxaluria.
Por ejemplo,
- En noviembre de 2020, Bayer AG anunció el inicio de un programa de colaboración en materia de salud digital G4A con las cuatro nuevas empresas emergentes, centrado en enfermedades cardiometabólicas y renales, oncología y salud de la mujer. Esta colaboración tiene como objetivo dar forma al futuro de la atención sanitaria y apoyar a las empresas emergentes, además de aumentar el desarrollo comercial estratégico de la empresa.
La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de medicamentos para la hiperoxaluria secundaria, lo que también proporciona el beneficio a las organizaciones para mejorar sus ofertas de medicamentos para la hiperoxaluria secundaria.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET
5.1 REGULATORY FRAMEWORK FOR PROBIOTICS
5.2 REGULATORY FRAMEWORK FOR EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TARGETED TREATMENT FOR SECONDARY HYPEROXALURIA IS IN HIGH DEMAND
6.1.2 R&D INVESTMENT IN COMPANIES FOCUSING ON DRUG DEVELOPEMENT
6.1.3 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY
6.1.4 INCREASED NUMBER OF CASES FOR SECONDARY HYPEROXALURIA
6.1.5 LOSS OF OXALOBACTER FORMIGENES
6.2 RESTRAINTS
6.2.1 LIMITED OPERATING REVENUE
6.2.2 HIGH COST OF TREATING SECONDARY HYPEROXALURIA
6.2.3 LIMITED SECONDARY THERAPEUTICS OPTION FOR TREATMENT
6.3 OPPORTUNITIES
6.3.1 DIFFICULTY IN MAINTAINING LOW OXALATE DIET
6.3.2 INCREASING NUMBER OF BARIATRIC SURGERY
6.3.3 REGULATORY SUPPORT FOR APPROVAL
6.3.4 RISING DISPOSABLE INCOME
6.4 CHALLENGES
6.4.1 DELAY IN DIAGNOSIS OF DISEASE LEADING TO NEED FOR RENAL REPLACEMENT
6.4.2 INCREASE FITNESS AWARENESS AMONG PEOPLE
6.4.3 INCREASE FLUID INTAKE AS A PREVENTIVE MEASURES
7 COVID-19 IMPACT ON MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET
7.1 OVERVIEW
7.2 PRICE IMPACT
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC DECISIONS FOR MANUFACTURERS
7.6 CONCLUSION
8 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUPPLEMENTS
8.2.1 OXALATE BINDING AGENTS
8.2.1.1 CALCIUM SUPPLEMENTS
8.2.1.2 MAGNESIUM SUPPLEMENTS
8.2.1.3 OTHERS
8.2.2 CITRATE SUPPLEMENTS
8.2.3 PYRIDOXINE SUPPLEMENTS
8.2.4 PROBIOTICS
8.3 THIAZIDE DIURETICS
8.4 RELOXALIASE
9 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION
10 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 CHILDREN
11 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER
11.1 OVERVIEW
11.2 HOME HEALTHCARE
11.3 HOSPITALS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 ONLINE PHARMACIES
12.5 OTHERS
13 MIDDLE EAST & AFRICA SECONDARY HYPEROXLURIA DRUG MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST & AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 UAE
13.1.4 ISRAEL
13.1.5 EGYPT
13.1.6 REST OF MIDDLE EAST & AFRICA
14 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 COMPANY PROFILE
15.1 NESTLE
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 GLAXOSMITHKLINE PLC
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BAYER AG
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOW FOODS
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 SOLGAR INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 PHARMAVITE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 INFINITUS (CHINA)
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 MISSION PHARMACAL COMPANY
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 .RECENT DEVELOPMENT
15.9 OYSTER SHELL
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 ALLENA PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 AMWAY CORP.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CELEBRATE VITAMINS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 ENTRING, LLC
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 NATURE’S BOUNTY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 OXTHERA
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RENEW LIFE FORMULAS, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 SYNLOGIC
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TIENS
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA OXALATE BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA THIAZIDE DIURETICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA RELOXALIASE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA OVER THE COUNTER IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA PRESCRIPTION IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA ADULTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA CHILDREN IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA HOME HEALTHCARE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HOSPITALS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA OTHERS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA OTHERS PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 32 SOUTH AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 33 SOUTH AFRICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 34 SOUTH AFRICA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 SOUTH AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 36 SOUTH AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 37 SOUTH AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 SOUTH AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 SAUDI ARABIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 SAUDI ARABIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 SAUDI ARABIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 SAUDI ARABIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 43 SAUDI ARABIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 SAUDI ARABIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 SAUDI ARABIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 UAE SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 UAE SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 UAE OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 UAE SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 UAE SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 51 UAE SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 52 UAE SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 53 ISRAEL SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 ISRAEL SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 ISRAEL OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 ISRAEL SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 ISRAEL SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 58 ISRAEL SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 59 ISRAEL SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 60 EGYPT SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 EGYPT SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 EGYPT OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 EGYPT SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 EGYPT SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 65 EGYPT SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 EGYPT SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 REST OF MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 12 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET IN 2021 & 2028
FIGURE 14 REGULATORY FRAMEWORK FOR PROBIOTICS
FIGURE 15 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET
FIGURE 16 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020
FIGURE 17 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2020
FIGURE 21 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUGS CLASS, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 23 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020
FIGURE 25 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 27 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020
FIGURE 29 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 31 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 33 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 35 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: SNAPSHOT (2020)
FIGURE 37 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2020)
FIGURE 38 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE (2021-2028)
FIGURE 41 MIDDLE EAST & AFRICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
